Physician profile
Ingrid E Berdo
NPI 1790169829
$3,361.94
in general payments reported to CMS, 2019-2025
24 companies · $699 in 2025
The $699 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $1,026 · 2023: $463 · 2024: $649 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $409.38 | 2022-2023 | Nuplazid |
| Abbvie INC. | $331.98 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $307.49 | 2021-2022 | |
| Lilly USA, LLC | $193.09 | 2023-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $151.76 | 2022-2025 | |
| Amgen INC. | $141.04 | 2021 | |
| Neurocrine Biosciences, INC. | $129.25 | 2025 | |
| Ibsa Pharma INC. | $125.00 | 2024 | Tirosint |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $124.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $124.16 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $122.00 | 2024 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $121.60 | 2022 | |
| Ucb, INC. | $118.06 | 2025 | Nayzilam |
| Axsome Therapeutics, INC. | $114.10 | 2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $109.71 | 2022 | |
| Jazz Pharmaceuticals INC. | $105.69 | 2022 | |
| Lundbeck LLC | $104.17 | 2025 | Rexulti |
| Neurelis, INC. | $89.60 | 2024 | Valtoco |
| Astellas Pharma US INC | $89.45 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.70 | 2022 | |
| Pfizer INC. | $62.71 | 2025 | |
| Novo Nordisk INC | $61.77 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Berdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.